http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
RedHill Biopharma (RDHL) Announces New USPTO Patent Covering Talicia Through 2034
-
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
-
RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
-
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
-
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
-
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
-
RedHill Biopharma (RDHL) Announces 10M Share Offering at $0.80/sh
-
RedHill Biopharma Announces $8 Million Registered Direct Offering
-
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
-
RedHill (RDHL) and U.S. Army Report Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
-
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
-
RedHill Biopharma (RDHL) Regains Nasdaq Compliance
-
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
RedHill Biopharma (RDHL) Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
-
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
-
RedHill Biopharma (RDHL) Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034
-
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
-
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
-
RedHill Biopharma (RDHL) and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
-
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
-
RedHill Biopharma (RDHL) Receives NASDAQ Non-compliance Notice
-
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
RedHill Biopharma (RDHL) Announces FDA sNDA Approval for Talicia
-
RedHill Announces FDA sNDA Approval for Talicia®
-
RedHill Biopharma (RDHL) announced U.S. patent allowance for new opaganib patent
-
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
-
This Week in Health News: 11 Stories You Need to See
-
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
-
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
-
RedHill Biopharma's (RDHL) RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial
-
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
-
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
-
RedHill Biopharma (RDHL) Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
-
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
-
RedHill Biopharma (RDHL) Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
-
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
-
Phil and RedHill Biopharma Partner to Increase Access to Talicia®
-
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
-
RedHill Biopharma (RDHL) Provides R&D Update
-
RedHill Provides R&D Update
-
RedHill Biopharma (RDHL) Receives NASDAQ Non-compliance Notice
-
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
-
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
-
RedHill Biopharma's (RDHL) RHB-102 and Opaganib Granted New Patents in Oncology Setting
-
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
-
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
-
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
-
RedHill Biopharma (RDHL) Announces $6 Million Registered Direct Offering of ADSs and Warrants
-
RedHill Biopharma Announces $6 Million Registered Direct Offering